IP Library Patent Application 18819941
Patent Application
App. No. 18/819,941

COMPOSITIONS AND PROCESSES FOR IMPROVED MASS SPECTROMETRY ANALYSIS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/819,941
Abstract

The invention provides a novel additive for improved analysis by mass spectrometry. More specifically, ascorbic acid has been found to reduce or eliminate the presence of adducts commonly present in mass spectra. The improved processes and compositions of the invention allow for increased accuracy, sensitivity and throughput for samples analyzed by mass spectrometry.

Claims (31)

1 . (canceled)

2 . A matrix composition for analysis by mass spectrometry, comprising:

a matrix material selected from the group consisting of 3-hydroxypicolinic acid (3-HPA), di-ammonium citrate (DAC), or a combination thereof; and

an adduct-reducing additive comprising ascorbic acid, or a salt, tautomer or analog thereof, wherein the molar ratio of the adduct-reducing additive to the matrix material is about 1:20, about 1:19, about 1:18, about 1:17, about 1:16, about 1:15, about 1:14, about 1:13-or about 1:12.

3 . The matrix composition of claim 2 , further comprising ammonium oxalate.

4 . The matrix composition of claim 2 , wherein the matrix material is 3-hydroxypicolinic acid (3-HPA).

5 . The matrix composition of claim 4 , wherein the molar ratio of the adduct-reducing additive to the matrix material is about 1:15.

6 . The matrix composition of claim 5 , further comprising ammonium oxalate.

7 . The matrix composition of claim 6 , wherein the molar ratio of ammonium oxalate to the matrix material is about 1:15.

8 . The matrix composition of claim 2 , wherein the adduct-reducing additive comprises ascorbic acid.

9 . The matrix composition of claim 2 , wherein the analog of ascorbic acid comprises the formula:

wherein:

R 1 and R 2 independently are OH, halogen, R 3 , OR 3 , azido, cyano, CH 2 R 3 , CHR 3 R 4 , SR 3 , NR 3 R 4 , and R 1 and R 2 are not both OH; and

R 3 and R 4 independently are H, alkyl, acetylene or cyano, or an optionally substituted aryl carbocyclic ring, aryl heterocyclic ring, non-aryl carbocyclic ring or non-aryl heterocyclic ring.

10 . A composition for analysis by mass spectrometry, comprising:

a nucleic acid analyte;

a matrix material selected from the group consisting of 3-hydroxypicolinic acid (3-HPA), di-ammonium citrate (DAC), or a combination thereof; and

an adduct-reducing additive comprising ascorbic acid, or a salt, tautomer or analog thereof.

11 . The composition of claim 10 , wherein the nucleic acid is deoxyribonucleic acid.

12 . The composition of claim 10 , wherein the nucleic acid is ribonucleic acid.

13 . The composition of claim 10 , further comprising ammonium oxalate.

14 . The composition of claim 10 , wherein the molar ratio of the adduct-reducing additive to the matrix material is about 1:20, about 1:19, about 1:18, about 1:17, about 1:16, about 1:15, about 1:14, about 1:13-or about 1:12.

15 . The composition of claim 2 , wherein the matrix material is 3-hydroxypicolinic acid (3-HPA).

16 . The composition of claim 15 , wherein the molar ratio of the adduct-reducing additive to the matrix material is about 1:15.

17 . The composition of claim 16 , further comprising ammonium oxalate.

18 . The composition of claim 17 , wherein the molar ratio of ammonium oxalate to the matrix material is about 1:15.

19 . The composition of claim 10 , wherein the adduct-reducing additive comprises ascorbic acid.

20 . The composition of claim 10 , wherein the analog of ascorbic acid comprises the formula:

wherein:

R 1 and R 2 independently are OH, halogen, R 3 , OR 3 , azido, cyano, CH 2 R 3 , CHR 3 R 4 , SR 3 , NR 3 R 4 , and R 1 and R 2 are not both OH; and

R 3 and R 4 independently are H, alkyl, acetylene or cyano, or an optionally substituted aryl carbocyclic ring, aryl heterocyclic ring, non-aryl carbocyclic ring or non-aryl heterocyclic ring.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2024
From: BECKER, THOMAS
To: SEQUENOM, INC.
Reel/Frame 069670/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2024
From: SEQUENOM, INC.
To: BIOSCIENCES ACQUISITION COMPANY
Reel/Frame 069670/0735 →
CHANGE OF NAME Recorded Dec 23, 2024
From: BIOSCIENCES ACQUISITION COMPANY
To: AGENA BIOSCIENCE, INC.
Reel/Frame 069764/0814 →